Long-term efficacy of imatinib for treatment of metastatic GIST. (Q38090470)

28 August 2017

title

Long-term efficacy of imatinib for treatment of metastatic GIST. (English)

1 reference

28 August 2017

1 reference

ChEBI release 2020-05-28

Shreyaskumar Patel

1

1 reference

28 August 2017

publication date

17 March 2013

1 reference

Cancer Chemotherapy and Pharmacology

28 August 2017

published in

1 reference

28 August 2017

volume

72

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

277-286

1 reference

Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

Gastrointestinal stromal tumors: recent advances in understanding of their biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

Management of malignant gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

Molecular pathobiology of gastrointestinal stromal sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

New developments in gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

Biology of gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

An update on molecular genetics of gastrointestinal stromal tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

Imatinib mesylate--a new oral targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

Practical management of tyrosine kinase inhibitor-associated side effects in GIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2135-8

10.1007/S00280-013-2135-8

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1025573964

0 references

1 reference